M&A Already Underway As Angelini Acquires Arvelle
Will Commercialize Epilepsy Drug Cenobamate In Europe
Executive Summary
2020 has kicked off with a major European biotech deal that will see the Italian conglomerate Angelini take over Switzerland's Arvelle which is on the verge of getting EU approval for an anti-epilepsy drug licensed from SK Bio that got the green light in the US two years ago.
You may also be interested in...
EU Approval Verdicts Near For A Bumper Crop Of New Drugs
Novartis, Arvelle, AstraZeneca and Incyte are among a raft of drug sponsors who should find out shortly whether the European Medicines Agency will vote in favor of approving their products for use in the EU.
Deal Watch: Celgene CVR From BMS Buyout Falls Through
Another victim of the COVID-pandemic, Celgene's $9-per-share contingent value right tied to BMS obtaining approval of three drugs goes unrealized due to FDA travel restrictions slowing down site inspections. Clene goes public, United Therapeutics buys PRV from Y-mAbs.
Ovid Shifts Focus After Angelman Syndrome Drug Disappoints In Phase III
The Phase III clinical trial showed a noticeable placebo effect compared with OV101.